Baseline Risk and Longitudinal Changes in kidneyintelX.dkd and Its Association With Kidney Outcomes in the CANVAS and CREDENCE Trials.

Erik Moedt¹, Steven G Coca², Katherine Edwards³, Brendon L Neuen⁴, Clare Arnott^4,5, Stephan J L Bakker⁶, Fergus Fleming³, Hiddo J L Heerspink¹

¹Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.

²Barbara T. Murphy Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY.

³Renalytix AI, PLC, New York, NY.

⁴The George Institute for Global Health, University of South Wales, Sydney, New South Wales, Australia.

⁵Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

⁶Department of Internal Medicine, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.

PubMed PMC DOI PDF

Abstract

OBJECTIVE: We evaluated the prognostic and clinical utility of kidneyintelX.dkd, a biomarker-based risk score, in patients with type 2 diabetes and a broad range of chronic kidney disease (CKD) by assessing its association with kidney outcomes at baseline and longitudinally, comparing it with the established Kidney Disease Improving Global Outcomes (KDIGO) risk classification, and examining its re…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.